The Voltage-Dependent Anion Channel (VDAC) is a pivotal mitochondrial membrane protein that regulates the exchange of metabolites, ions, and ATP between mitochondria and the cytosol. Beyond its fundamental role in energy metabolism, VDAC is increasingly recognized for its involvement in apoptosis, cellular stress responses, and cancer metabolism. As a highly conserved and abundantly expressed protein on the mitochondrial outer membrane, VDAC represents an emerging drug target, particularly in oncology and neurodegenerative diseases. Its accessibility and functional centrality make it an attractive entry point for modulating mitochondrial function in disease contexts. At SEEDSUPPLY, we are advancing small-molecule discovery targeting VDAC using our proprietary binder screening platform, with the goal of unlocking novel therapeutic strategies in areas of high unmet medical need.

GPR101 is an orphan G protein–coupled receptor (GPCR) with no known endogenous ligand, yet its physiological and pathological roles are gaining increasing attention. Genetic studies have linked GPR101 overexpression to X-linked acrogigantism (X-LAG), a rare condition characterized by early-onset gigantism, suggesting its involvement in growth hormone regulation. As an uncharted member of the GPCR superfamily, GPR101 holds promise not only for endocrine disorders but also as a potential modulator in neuroendocrine and CNS-related pathways. Its orphan status presents a unique opportunity for first-in-class drug discovery. SEEDSUPPLY is leveraging its platform to discover and optimize novel binders for GPR101, aiming to decode its function and therapeutic potential through a ligand-first approach.